Cargando…
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV in...
Autores principales: | Ma, Jie, Li, Huan, Hu, Xiangnan, Yang, Lu, Chen, Qi, Hu, Congli, Chen, Zhihao, Tian, Xiaoyan, Yang, Yang, Luo, Ying, Gan, Run, Yang, Junqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390258/ https://www.ncbi.nlm.nih.gov/pubmed/28406239 http://dx.doi.org/10.1038/srep46628 |
Ejemplares similares
-
Calorimetry at the CMD-3 Detector
por: Razuvaev, G P, et al.
Publicado: (2017) -
Correction of abnormal matrix formed by cmd/cmd chondrocytes in culture by exogenously added cartilage proteoglycan
Publicado: (1986) -
The CMD-3 Data Acquisition System
por: Kozyrev, A N, et al.
Publicado: (2017) -
CMD-2M Detector Project
por: Aulchenko, V M, et al.
Publicado: (2001) -
12/15-Lipoxygenase Regulation of Diabetic Cognitive Dysfunction Is Determined by Interfering with Inflammation and Cell Apoptosis
por: Chen, Qi, et al.
Publicado: (2022)